MCF7/AnaR-1 Cell Line
MCF7/AnaR-1 is a cell culture model mimicking acquired resistance of aromatase inhibitors (AIs) – an anti-cancer therapy. This breast cancer cell line was established from MCF7/S0.5 cells, which originates from MCF7 cells. The cellular classification is epithelial, and their shape is polygonal. The MCF7/AnaR-1 cell line is resistant to the third generation AI – anastrozole […]
Contributors
| Inventor | Institute |
|---|---|
| Anne Lykkesfeldt | Danish Cancer Society, Denmark |
| Cat. #: | 152551 |
|---|---|
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Breast cancer |
| Research Fields: | Cancer;Drug development |
| Organism: | Human |
| Tissue: | Breast |
| Gender: | Female |
| Growth properties: | Adherent: breast cancer cell line resistant to the aromatase inhibitor anastrozole. Estrogen receptor positive. |
| Cancer Types In Detail: | Breast cancer |
| Primary citation: | Hole et al. 2015. Int J Oncol. 46(4):1481-1490. PMID: 25625755. |
| Alternate name: | MCF-7/AnaR-1; AnaR-1 |
|---|---|
| Product description: | MCF7/AnaR-1 is a cell culture model mimicking acquired resistance of aromatase inhibitors (AIs) – an anti-cancer therapy. This breast cancer cell line was established from MCF7/S0.5 cells, which originates from MCF7 cells. The cellular classification is epithelial, and their shape is polygonal. The MCF7/AnaR-1 cell line is resistant to the third generation AI – anastrozole (Arimidex). MCF/AnaR-1 is oestrogen receptor positive. Third generation AIs have proven to be effective treatment for oestrogen receptor positive (ER+) breast cancer and therefore are recommended as first line endocrine therapy for postmenopausal ER+ breast cancer patients. Previous applications of this cell line include western blot analysis of protein expression. Since molecular mechanisms of AI resistance are largely undisclosed, the development of cell lines resistant to the non-steroidal AI anastrozole allows the study of the molecular basis for AI resistance to find new targets for treatment. |
| Gender: | Female |
| Conditional: | No |
| Production details: | Anastrozole-resistant cell lines were established from MCF7/S0.5 cells grown in medium with 10% NCS and 10-7 M testosterone. A culture of MCF7/S0.5 cells were treated with 10-7 M anastrozole for one week, trypsinised and seeded in serial dilutions in 24-well plates. Single colonies were transferred to new wells and gradually expanded in medium with anastrozole. After 2-3 months, the isolated colonies gave rise to anastrozole-resistant cell lines, which could be grown in anastrozole-containing medium with a weekly split ratio of 1:25. This cell line was authenticated in January 2014 by DNA profiling using short tandem repeat loci and found to be matching the genetic profile reported for the MCF7 cell line. |
| Cellosaurus ID: | CVCL_5A09 |
| Parental cell line: | MCF7/S0.5 |
| disease: | Cancer |
| Format: | Frozen |
|---|---|
| Shipping conditions: | Dry ice |
| Growth medium: | Phenol-red-free DMEM/F12 medium supplemented with 10% newborn calf serum, 2.5 mM Glutamax, 6 ng/ ml insulin, 0.1 uM testosterone and 0.1 uM anastrozole. |
| Temperature: | 37° C |
| Atmosphere: | Humidified air with 5% CO2 |
| References: |
Thewes et al. 2017. Oncogene. 36(29):4124-4134.PMID: 28319069. Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-726. PMID: 25667100. Hole et al. 2015. Int J Oncol. 46(4):1481-1490. PMID: 25625755. |
|---|
Related Tools for Cell lines
| Cat. # | Tool Name | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151014 | MCF7 AREc32 Cell Line |
Key Info
MCF7 AREc32 Cell Line
|
View Tool | |||||||||||||
| 151425 | TR146 Cell Line |
Key Info
TR146 Cell Line
|
View Tool | |||||||||||||
| 151449 | JIM1 Cell Line |
Key Info
JIM1 Cell Line
|
View Tool | |||||||||||||
| 151450 | JIM3 Cell Line |
Key Info
JIM3 Cell Line
|
View Tool | |||||||||||||
| 151479 | HCT 116 p300 KO [D10] Cell Line |
Key Info
HCT 116 p300 KO [D10] Cell Line
|
View Tool | |||||||||||||
